Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.

BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is commonly caused by mutations in the LDLR, APOB or PCSK9 genes, with untreated mean low density lipoprotein-cholesterol (LDL-C) concentrations being elevated in APOB mutation carriers, even higher in LDLR mutation and highest in those with a PCSK9 mutation. Here we examine this in children with FH from Norway, UK, The Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. METHODS: Differences in characteristics and pre- and post-treatment lipid concentrations in those with different molecular causes were compared by standa... Mehr ...

Verfasser: Futema, Marta
Ramaswami, Uma
Tichy, Lukas
Bogsrud, Martin P
Holven, Kirsten B
Roeters van Lennep, Jeanine
Wiegman, Albert
Descamps, Olivier S
De Leener, Anne
Fastre, Elodie
Vrablik, Michal
Freiberger, Tomas
Esterbauer, Harald
Dieplinger, Hans
Greber-Platzer, Susanne
Medeiros, Ana M
Bourbon, Mafalda
Mollaki, Vasiliki
Drogari, Euridiki
Humphries, Steve E
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Verlag/Hrsg.: Elsevier
Schlagwörter: Austria / Belgium / Child / Czech Republic / DNA Mutational Analysis / Europe / Greece / Humans / Hyperlipoproteinemia Type II / Lipids / Mutation / Netherlands / Norway / Portugal / Proprotein Convertase 9 / Receptors / LDL / Heterozygous familial hypercholesterolaemia / LDL-C concentrations / Mutation spectrum / Statin treatment
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27352234
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/261190